You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
NEWS ARCHIVE

14-05-2020

KEDPLASMA USA COLLECTS FIRST UNIT OF COVID-19 CONVALESCENT PLASMA

  • Slide Image Slide Image Slide Image
  1. 1

This plasma will be supplied to Kedrion Biopharma to develop a potential anti-COVID immune globulin therapy.

In order to tackle the serious health emergency caused by the COVID-19 pandemic On May 12, 2020, KEDPLASMA USA collected their first unit of COVID-19 Convalescent plasma in their Mobile, Alabama center.  

KEDPLASMA USA, the plasma collection unit of Kedrion Biopharma, will supply COVID-19 convalescent plasma to develop and produce an anti-COVID immunoglobulin, which if proven to be effective, will be used to treat those infected with the coronavirus.  

Kedrion Biopharma 's R&D department has begun work to develop a potential immunoglobulin therapy in the shortest possible time.  The company will use “convalescent plasma” (donated by patients who have recovered from the disease, and is believed to be rich in anti-virus antibodies to extract immunoglobulin, which will then be produced on an industrial scale.

KEDPLASMA USA, with the approval of the Food and Drug Administration (FDA), has begun collecting COVID-19 convalescent plasma in twenty three collection centers, and will expand collections where appropriate in the future.

KEDPLASMA USA is proud to collecting this very special plasma during the COVID-19 pandemic”, said Helen Nasser, KEDPLASMA USA Managing Director, “The unselfish act of donating lifesaving plasma is treasured each day, but during this difficult coronavirus period, and knowing we can potentially treat this terrible disease, we are honored to collect this important plasma”

 

For more information please contact: contactus@kedplasmausa.com